레이저옵텍 인터내셔널 웹페이지로 이동합니다. 인터내셔널 웹페이지의 내용은 해당 언어지역에서의 제품 정보에 관한 것으로 국내 제품 과는 품 목이 다를 수 있으며, 국내 소비자의 보호를 위한 국내법 상의 광고 심의,규제를 받지 않습니다. 페이지 이동을 계속하겠습니까?


You will be moved to the Laseroptek products web page. The content in the International web page contains product information in that region. The items may be different from the Korean products, and are not regulated by the advertising reviews of Korean laws for the protection of Korean cousumers. Would you like to continue moving to the page?

X

PALLAS

Products > PALLAS

device

pallas

PALLAS is a revolutionary, first of its kind solid state
308/311 Ultraviolet laser system specifically designed to
efficaciously treat complicated skin conditions such as
vitiligo, psoriasis, atopic dermatitis and alopecia areata.
UNDERSTANDING VITILIGO AND PSORIASIS

Vitiligo is a relatively common disease, which is acquired depigmentation disorder affecting people of all ages and both sexes equally. This skin disorder has major negative effects on a patient’s quality of life, with about 1% of the world’s population affected, which means over 50 million people are affected.

The prevalence of vitiligo is often said to range from 0.06 to 2.28% in the general populations and from 0 to 2.16% in children populations.


Psoriasis is a common skin condition that speeds up the life cycle of skin cells. It causes cells to build up rapidly on the surface of the skin. Psoriasis is a chronic disease that often comes and goes.

Psoriasis affects people of all ages, and in all countries. It is a serious global problem with at least 100 million individuals affected worldwide. A total of 125 million people is suffering from psoriasis in the world and there’re as many as 7.5 million patients in the United States.

Psoriasis occurs worldwide. It affects men and women of all ages, regardless of ethnic origin, in all countries. Published data on the prevalence of psoriasis in countries vary between 0.09% and 11.4%. In most developed countries, prevalence is between 1.5 and 5%. There is also evidence to suggest that the prevalence of psoriasis may be increasing. Many studies have demonstrated that psoriasis can impact substantially on QoL.

WORLD’S FIRST SOLID STATE UV LASER

PALLAS is the world’s very first UV (ultraviolet) laser indicated for treatment of dermatological conditions. PALLAS is effective in psoriasis, vitiligo, atopic dermatitis, and alopecia areata. LASEROPTEK has spent the last decade researching and designing the PALLAS, the world’s first solid 311nm UV laser, which is a narrow band UVB and has been proven the most safe and effective wavelength in treating many skin disorders, including psoriasis and vitiligo.
OPTIMAL WAVELENGTH

310-313nm wavelength range (narrow band UVB) was well-known for the most effective wavelength range to treat complicated skin conditions, such as vitiligo and psoriasis, getting away from the wavelength of undesirable burning effects. Its efficacy and safety was studied and published in many papers.

LASEROPTEK chose 311nm wavelength which is closer to UVB wavelength for a deeper penetration among 310-313nm. This 311nm wavelength has been demonstrated as equally effective as 308nm which is being used popularly.

PROVEN EFFICACY AND SAFETY

Laser treatment has an advantage in treating vitiligo and psoriasis in a targeted manner and is a reasonable treatment option for localized vitiligo and psoriasis. PALLAS, a gain-switched 311nm Ti:sapphire laser (TSL) was developed based on the of narrow-band UVB.

PALLAS has proven its efficacy by providing patients with relief in fewer treatments than topical or conventional phototherapy. PALLAS can effectively treat anatomical locations difficult to treat. PALLAS treatment is painless and long-lasting.

The therapeutic mechanism of Ti-Saphhire laser would involve immune modulation and melanocyte stimulation, as in narrow-band UVB and excimer laser treatment. In addition, the 311nm wavelength of TSL can penetrate deeper than the 308nm wavelength of excimer lasers.

Its efficacy in treatment of vitiligo was studied by Professor Jung Min Bae, MD, PhD of Department of Dermatology, St. Vincent’s Hospital, published in JAMA Dermatology in 2017.

PROMISING FOR THERAPEUTIC OPTION FOR ATOPIC DERMATITIS
AND ALOPECIA AREATA

PALLAS has also proven that it is an effective adjuvant treatment modality for atopic dermatitis (AD).

In the animal study conducted by Professor Beom Joon Kim of Department of Dermatology, Chung-Ang University College of Medicine, the results suggest that, in AD mouse models, the gain-switched 311nm Ti:Sapphire laser suppresses the hyperproduction of IgE and of T-helper cell type 2 (Th2) cytokines. The data demonstrated that PALLAS improves the severity and symptoms of AD in this murine model. In addition to the clinical features of AD, the gain-switched 311nm Ti:Sapphire laser also reduces the skin thickening and mast cell infiltration in inflamed AD skin lesions. Moreover, the gain-switched 311nm Ti:Sapphire laser was also able to modulate the immune response, including hyper-IgE and upregulated Th2 cytokines. As a result, PALLAS improves skin barrier function in AD lesions and inhibits Th2 mediated inflammatory reaction showing the therapeutic effectiveness.

This study result was published in Lasers in Medical Science, July 2016.

In addition, Recently PALLAS has shown its potential in therapeutic effect in alopecia areata, too. More studies are ongoing.

SYSTEM SPECIFICATIONS

관련내용 설명
Laser type Ti:Sapphire
Wavelength 308nm / 311nm
Pulse duration 15 ~ 20ns
Pulse Energy (max) 5mJ
Repetition rates 100Hz
Spot size 12 x 12 mm² (Square)
Display 10.4” TFT LCD Touch panel
Electrical control ARM processor
Cooling system Closed cycle water to air heat exchanger
Chiller
Electrical Power 220-230VAC, 50/60Hz
PALLAS DETAILS

BEFORE & AFTER

Psoriasis
  • Before

  • After

Vitiligo
  • Before

  • After

Vitiligo
  • Before

  • After

Psoriasis
  • Before

  • After

Vitiligo
  • Before

  • After

Vitiligo
  • Before

  • After